Cargando...

HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience

Erythropoiesis-stimulating agents, such as recombinant human erythropoietin, are commonly used for the treatment of anemia in patients with chronic kidney disease (CKD). In 2007, HX575 (Binocrit(®)) became the first biosimilar epoetin alfa to be approved by the European Medicines Agency (EMA). The d...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Drug Des Devel Ther
Main Authors: Dellanna, Frank, Goldsmith, David, Krendyukov, Andriy, Seidl, Andreas, Höbel, Nadja, Combe, Christian
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2017
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739117/
https://ncbi.nlm.nih.gov/pubmed/29296077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S146147
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!